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While the ancient Egyptians and Greeks used honey for wound care, and a broad spectrum of
wounds are treated all over the world with natural unprocessed honeys from different sources,
MedihoneyTM has been one of the first medically certified honeys licensed as a medical product
for professional wound care in Europe and Australia. Our experience with medical honey in
wound care refers only to this product. In this review, we put our clinical experience into
a broader perspective to comment on the use of medical honey in wound care. More
prospective randomized studies on a wider range of types of wounds are needed to confirm the
safety and efficacy of medical honey in wound care. Nonetheless, the current evidence
confirming the antibacterial properties and additional beneficial effects of medical honey on
wound healing should encourage other wound care professionals to use CE-certified honey
dressings with standardized antibacterial activity, such as MedihoneyTM products, as an
alternative treatment approach in wounds of different natures.
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Introduction
In our paediatric oncology department at the Children’s
Hospital Medical Centre, University of Bonn, Germany
most patients suffer from a profoundly suppressed
immune system, due to their underlying disease
(i.e. leukemia) (1) and the chemotherapy they undergo.
This frequently results in wound healing problems (2,3),
leaving the patient susceptible to wound infections.
Unfortunately these infections spread easily in immuno-
compromized patients and can cause secondary poten-
tially life-threatening bloodstream infections (4).
Five years ago a 12-year old patient was submitted to
our unit. Doctors at another hospital had removed an
abdominal lymphoma, leaving an open drainage site on
his abdomen. On admission, his wound was infected
with methicillin-resistant Staphylococcus aureus (MRSA).
In order to avoid nosocomial spread, the patient was
immediately isolated, a difficult situation for the child to
comprehend with significant additional costs from the
perspective of the hospital. Although the patient was
scheduled to receive chemotherapy, treatment could not
commence until the infection cleared. The wound was
treated with a local antiseptic (octenidin) for 12 days.
Since no improvement occurred, we decided to use an
Australian medical honey (MedihoneyTM), which con-
tains leptospermum honey, a type with excellent in vitro
activity against MRSA (5–7). The wound was free of
bacteria two days later, and the chemotherapy against the
underlying illness could be started.
While the ancient Egyptians and Greeks used honey for
wound care, a broad spectrum of wounds are treated all
over the world with natural unprocessed honeys from
different sources (8–13), MedihoneyTM has been one of
the first medically certified honeys licensed as medical
product for professional wound care in Europe and
Australia (14,15). Our experience with medical honey in
wound care refers only to this product. We were asked by
one of the editors of eCAM to put our clinical experience
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(2,16) into a broader perspective and to comment on the
use of medical honey in wound care (Table 1).
What Makes Medical Honey Effective?
Honey works differently from antibiotics, which attack
the bacteria’s cell wall or inhibit intracellular metabolic
pathways. Honey is hygroscopic, meaning it draws
moisture out of the environment and thus dehydrates
bacteria. Its sugar content is also high enough to hinder
the growth of microbes, but the sugar content alone is
not the sole reason for honey’s antibacterial properties.
When honey is diluted with water, reducing its high
sugar content, it still inhibits the growth of many
different bacterial species that cause wound infections
(14,15,17–20).
Leptospermum spp. are known by a number of common
names in Australia and New Zealand including Tea Tree,
Manuka, Goo Bush and Jelly Bush. A least 79 species of
Leptospermum have been described in Australia and New
Zealand (21). The medical honey, our clinical experience
refers to (MedihoneyTM), consists of standard mixture of
different Leptospermum spp. honeys (Fig. 1), and exhibits
a standard antibacterial activity as confirmed by appro-
priate in vitro testing methods (22).
Unlike glucose oxidase, the antibacterial properties
from Leptospermum spp. honeys are light- and heat-
stable. Neither type of activity is influenced by the final
sterilizing procedure of gamma-irradiation (23). Over 100
substances are candidates for the particular antibacterial
property of these honeys, but the active ingredient has
not yet been identified. Even if the hydrogen peroxide
activity is blocked and the osmotic effect of honey is
circumvented by dilution, selected honeys from
Leptospermum spp. still display significant antibacterial
effects. Natural honey of other sources can vary as much
as 100-fold in the potency of their antibacterial activity
(which is due to hydrogen peroxide) (5–7,24–27).
In addition to its antibacterial properties, medical
honey hastens the healing of wounds through its anti-
inflammatory effects. The amount of wound exudate is
related to the activity of the local inflammatory process,
Table 1. Key information from this review
What makes medical honey effective? Medical honey is hygroscopic, meaning it draws moisture out of the environment and thus
dehydrates bacteria. The enzyme glucose oxidase, produces gluconic acid and minute amounts of
hydrogen peroxide when in contact with the wound surface.
In addition, each charge contains light- and heat-stable, in vitro confirmed antibacterial properties
from Leptospermum spp. honeys.
The pH level of honey is low (mean 4.4). Bacterial colonization or infection and recalcitrant wound
healing situations are often accompanied by high pH values in wound exudates and lowering the pH
speeds healing.
Why is medical honey irradiated? Honey may contain spores from Clostridium botulinum, which are inactivated. The ready to use
product is delivered sterile.
What is MedihoneyTM? Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose
oxidase and Leptospermum compounds which contribute to its antibacterial activity.
Legal background MedihoneyTM is licensed for wound care in Australia, Europe and the USA. In Europe a
CE-certification exists declaring MedihoneyTM as medical product.
Practical advances Medical honey dressings are easy to change without pain and without harm to the regenerating
tissue.
Malodour from recalcitrant wounds as a result of critical colonization and partial tissue necrosis is
successfully abandoned with medical honey due to its antibacterial, anti-inflammatory and debriding
effects.
Medical honey can be used in all different stages of wound healing, in many different types of
wounds and even in patients with diabetes.
Medical honey is well accepted by most patients and their families.
Drawbacks Some patients (5 out of 100) experience pain after the application of medical honey to the wound. In
some of them, treatment with medical honey has to be stopped.
Few patients with pre-existing atopic diseases show local atopic reactions. No severe systemic atopic
reaction due to medical honey has been reported in the literature.
Medical honey has to be kept in the wound for 12–24 h a day. Thus, it is combined with particular
dressings like calcium alginates of hydrofiber dressings, which add substantially to the overall cost of
treatment.
Depending on the amount of exudate, the dressing with medical honey has to be changed up to 2
times a day in acute inflammatory wounds. The most often practised change interval for medical
honey dressings is every 24–48 h.
Scientific evidence# For MedihoneyTM: one prospectively randomized controlled study considering the prevention of
catheter-related bacteremias in patients with dialysis catheters.
Many in vitro studies and animal studies confirming the antibacterial properties and the positive
effects on wound healing. Growing body of clinical experiences and observational studies derived
from independent wound care facilities all over the world.
#For the medical use of honey in general please refer to the outstanding review of Peter Molan from 2006 (15)
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in particular in wounds, which are colonized or infected
with bacteria. Thus, the anti-inflammatory action of
honey reduces oedema and the amount of exudate by
down regulating the inflammatory process. It also
reduces pain, as the pain in wounds results from the
nerve endings being sensitized by prostaglandins pro-
duced in the process of inflammation, as well from the
pressure on tissues resulting from oedema.
Due to its high sugar content, honey also prevents pain
on dressing changes as it keeps the wound surface moist
by mobilizing the oedema from the surrounding tissues.
The anti-inflammatory action of honey has been exten-
sively observed clinically (19,28,29) and in animal models
(15). Animals do not demonstrate any placebo effects, as
they are incapable of having attitudes influence their
healing process, such as believing that natural products
would bemore effective, or from hearing via the newsmedia
of the effectiveness of honey in wound treatment (30). Thus,
these observational and histological studies can be cited as
convincing evidence for the positive results with honey not
being due to a placebo effect. Similarly, this can be
concluded also for the observations in wounds in animal
models of honey stimulating the rate of angiogenesis,
granulation and epithelialization (31,32), which would
explain the findings in clinical trials that honey speeds up
the healing process (15).
Although the mechanism(s) by which honey speeds up
the healing process have not been determined, there are
some findings, which provide possible explanations. One
way in which honey may work is through its stimulation
of an inflammatory response in leukocytes (28,29,33), as
inflammation is what triggers the cascade of cellular
events that give rise to the production of growth factors
which control angiogenesis and proliferation of fibro-
blasts and epithelial cells. Very recently, Tonks et al.
discovered a 5.8 kDA component of manuka honey
which stimulates the production of TNF-a in macro-
phages via Toll-like receptor 4 (34).
Another mechanism may be related to the pH level of
honey being low (3.4–5.5; mean 4.4) (35,36). Bacterial
colonization or infection and recalcitrant wound healing
situations are often accompanied by pH values >7.3 in
wound exudates (37,38). It has been demonstrated that
acidification of wounds speeds healing (39), this being
attributed to the low pH increasing the amount of oxygen
off-loaded from hemoglobin in the capillaries. More
recently it has also been attributed to suppression of
protease activity in wounds by getting away from the
neutral pH that is the optimum for their activity (37).
Excessive protease activity in a wound can slow or prevent
healing by destroying growth factors (which are proteins)
and destroying the protein fibres and fibronectin in the
wound matrix, attachment to which activates fibro-
blasts and is necessary for the migration of these and of
epithelial cells (http://www.worldwidewounds.com/2005/
august/Schultz/Extrace-Matric-Acute-Chronic-
Wounds.html). This protease activity results from excessive
inflammation. The anti-inflammatory activity of honey
would thus remove this impediment to healing, as would the
antibacterial activity working through removing infecting
bacteria stimulating the inflammatory response.
The remarkable debriding action of honey that has
been noted by many would also assist in this by removing
slough which is a rich source of bacteria to stimulate an
inflammatory response (19).
Last but not least, medical honey successfully manages
the problem of malodour from chronic colonized
wounds, which results in severe discomfort and social
isolation in these patients. We relate the experience of
one female patient with relapsed breast cancer after
chemotherapy and irradiation. Her husband informed us,
that other members of the family would not enter her
room, because her wound smelled like a ‘dead rabbit’.
This malodour problem was successfully eliminated with
the application of medical honey in 2 weeks.
Why is the Final Product Irradiated?
Clostridium botulinum spores pervade our environment,
existing in the soil, air, dust and raw agricultural pro-
ducts. Due to the possibility of Clostridial contamination
and many reports of infant botulism in the literature
since the first description of this syndrome in 1976,
Figure 1. Pictures of different Leptospermum spp. plants from Australia.
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it has been recommended by paediatricians, not to
feed infants with honey and to place warning labels
on packaging, as done in the United Kingdom and
Norway (36).
In deep wound cavities the possibility exists of an
anaerobic environment, where the spores could prolifer-
ate and produce botulinum toxin. Negative effects such
as paralysis and cardiac arrhythmia have been described
related to systemic effects of the toxin. To eliminate
botulism spores with heat, honey must be heated to
120C (248F) for 10min, which results in adverse
changes to some of honeys’ beneficial properties. Since
spores have occasionally been found in honey, each batch
of MedihoneyTM is gamma irradiated to inactivate spores
such as those from Clostridium spp. This does not have
a detrimental impact on the antibacterial activity of
honey. On the other hand, irradiating honey is only a
safety measure on the side of caution since we (40) could
not detect a single case report in the literature of
C. botulinum wound infection related to the use of non-
irradiated honey in wound care (41).
Medihoney is not an Antiseptic
An ideal wound antiseptic would meet the following
criteria (42):
 Fast onset of bactericidal action and a remnant,
broad spectrum effect against bacteria and fungi,
even under the unfavorable conditions of exudating,
colonized or infected wounds.
 Enhancement and acceleration of the physiologic
process of wound healing (debridement, granula-
tion), even if applied for prolonged periods.
 No adverse local or systemic effects (allergy, toxicity
related to absorption).
 Moderate cost even if applied two times daily.
Medihoney meets all of the above criteria except
‘a fast onset of activity’, as it does not seem to produce
the desired reduction of bacteria (more than five log
steps) and fungi in 1–10min to be qualified as an
antiseptic.
What About Conventional Wound Care
Products in Paediatric Oncology?
Some of the parents in our unit have at first been sceptical
about the benefits of honey in wound care. However, the
scientific evidence for using conventional wound care
products in paediatric oncology patients is non-existent,
since no prospective randomized studies have been per-
formed in this particular population and no research has
been done on the long-term effects of modern conventional
treatments such as silver dressings.
There has been a report of a Silver-coated dressing which
caused raised liver enzymes and an argyria-like syndrome in
an adolescent burn patient (43). Another common treat-
ment is povidone iodine, which has the advantage of
antiseptic properties and is well suited for skin disinfection
prior to invasive procedures. However, the antiseptic
activity of iodine products is hampered by interactions
with the protein content of the wound exudate and severe
adverse effects of systemic absorption of iodine on thyroid
function must be considered in infants and toddlers as well
as in adult patients with latent hyperthyreosis.
In principle, the same problem exists with alcohol-
containing antiseptics, since they are almost completely
absorbed and need to be metabolized by the children,
who are treated concomitantly with many other drugs. In
contrast, medical honey does not display the problem of
systemic absorption and thus can even be utilized in
patients with diabetes mellitus without adverse effects on
blood glucose levels.
Medical Honey in Severely
Immunocompromized Patients?
One of our patients with acute myeloic leukemia in
relapse had a wound infection with methicillin-resistant
coagulase-negative staphylococci after thoracic surgery for
invasive Aspergillus infection of the lung, but was
allocated to allogenic bone marrow transplantation.
Using medical honey, the infection was eliminated.
The patient continued to receive medical honey applica-
tions during and after the transplantation (Fig. 2), leading
Figure 2. Thoracotomy wound of a patient with acute myeloic leukemia after surgical site infection (MedihoneyTM was applied on a calcium-alginate
dressing and left in the wound for 24 h).
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to a successful healing without further local or systemic
complications.
Medical Honey for Recalcitrant Wounds
Many of the 150 wound care patients we have treated
with medical honey had previously received specialist
attention for recalcitrant wounds (2,3,16,44). When
treatment with honey was commenced, their wound
status changed to healing from non-healing (2,3,16,44).
Similar findings have been reported by others (19,45).
MedihoneyTM for the protection Of
Catheter Entry Sites
The clinical usefulness of hemodialysis catheters is limited
by increased infectious morbidity and mortality. Topical
antiseptic agents, such as mupirocin, are effective at
reducing this risk but have been reported to select for
antibiotic-resistant strains. Johnson et al. (46) performed
a randomized, controlled trial comparing the effect of
thrice-weekly exit-site application of MedihoneyTM versus
mupirocin on infection rates in patients who were
receiving hemodialysis via tunnelled, cuffed central
venous catheters. A total of 101 patients were enrolled.
The incidences of catheter-associated bacteremia in
honey-treated (n=51) and mupirocin-treated (n=50)
patients were comparable (0.97 versus 0.85 episodes per
1000 catheter-days, respectively; NS). No exit-site infec-
tions occurred. During the study period, 2% of staphy-
lococcal isolates within the hospital were mupirocin
resistant. Thrice-weekly application of standardized anti-
bacterial honey to hemodialysis catheter exit sites was
safe, cheap, and effective and resulted in a comparable
rate of catheter-associated infection to that obtained with
mupirocin (although the study was not adequately
powered to assess therapeutic equivalence).
The effectiveness of honey against antibiotic-resistant
microorganisms and its low likelihood of selecting for
further resistant strains suggest that this agent may
represent a satisfactory alternative means of chemopro-
phylaxis in patients with central venous catheters. In our
paediatric oncology unit, all entry sites of tunnelled central
venous catheters, which show any sign of inflammation or
dehiscence, are covered with medical honey.
Honey Treatment for Prevention of Oral
Mucositis and for Gingivitis
Many cancer patients suffer from mucositis, a side effect of
chemotherapy that attacks the entire gastrointestinal tract
from the mouth to the anus. The cancer treatment breaks
down the epithelial cells lining the tract, leaving the patient
prone to ulcerations and infections. These important and
beneficial cells replicate and divide rapidly, which is why in
a typical healthy individual wounds in the mouth heal
quickly. Chemotherapy does not distinguish between
healthy and malignant cells, attacking all that reproduce
rapidly, including these epithelial cells.
Thus 20–40% of all cancer patients receiving intensive
chemotherapy suffer from mucositis, the number climbs to
80% when chemotherapy and radiation are combined, and
staggers even higher in patients receiving treatment for
cancer in the head and neck area. Open sores in cancer
patients suffering from mucositis leave them susceptible to
infection. In a study conducted in 2003, Biswal et al. (47)
investigated the use of honey in 40 adult patients with head
and neck cancer. Patients consumed 20ml (one and one-
third teaspoon) of pure honey 15min before, 15min after
and 6 h post-treatment. There was significant reduction in
the symptomatic grade three-fourth mucositis (which
describes the necessity for morphine infusion and paren-
teral nutrition) among honey-treated patients compared
with controls; i.e. 20% versus 75% (P < 0.001).
The compliance of the honey-treated group of patients
was better than controls. A total of 55%patients treated
with topical honey showed no change or a positive gain
in body weight compared with only 25% in the control
arm (P=0.05). According to a recent review, honey has
potential for the treatment of periodontal disease, mouth
ulcers and other problems of oral health (48), and a trial
has demonstrated a statistically significant difference
between chewing gelled honey and chewing chewing-
gum in decreasing the number of bleeding sites on gums
with gingivitis (49).
Use of Honey for Wound Care in Neonates
Due to the safeness of MedihoneyTM, we used this product
for wound care in premature neonates. One infant patient
had a recalcitrant wound after surgical intervention for
meningomyelocele. The wound stagnated, and during
intensive care treatment, it became colonized with multi-
resistant Klebsiella oxitoca. Before treatment with
MedihoneyTM was initiated, the child had received numer-
ous intravenous antibiotics and many other conventional
wound care treatments to clear the wound, spending the
first 3 months of its life in the hospital. MedihoneyTM
dressings cleared the wound of the pathogen and allowed
the patient to be discharged after 3 weeks. The wound
healed completely without further surgical intervention.
Viardi et al. (40) published an impressive case series
including nine neonates with polymicrobial wound infec-
tion after surgery for congenital heart disease. All infants
were considered as treatment failures, since chlorhexidine
0.05% plus fusidic acid ointment plus systemic antibiotics
did not result in any improvement of the sternal wound
infection. All infants showed marked clinical improvement
after 5 days of treatment with topical application of 5–10ml
of fresh unprocessed (non-pasteurized, non-irradiated)
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honey twice daily. The wounds were closed, clean and
sterile in all infants after 21 days of honey application.
There were no adverse reactions to the treatment. In a
recent review for Neonatal Network, Susan Bell reviewed
the current literature dealing with the medical use of
medical honey in neonatal wound care. Nurses in her unit
are using medical honey for this purpose since 2005.
She came to the conclusion that the scientific evidence
regarding the use of honey for wound treatment in neonates
and infants is interesting, but still not strong. The sample
sizes in the available clinical studies were small; there were
no comparison groups and no randomization. She stated
that double-blinded randomized controlled clinical trials
with sufficient power are needed to determine the efficacy of
honey in both initial wound management and secondary
treatment of infected and poorly healing wounds. It has to
be questioned, how double or even single (on the side of the
patent) blinding can be established in studies, which
investigate medical honey for wound care and compare it
with other conventional modes of treatment.
Honey Treatment Against Viral Disease
Al-Waili et al. published a cross over trial (9) in which 16
adult patients with a history of recurrent attacks of
herpetic lesions, 8 labial and 8 genital, were treated by
topical application of honey for one attack and acyclovir
cream for another attack. For labial herpes, the mean
duration of attacks and pain, occurrence of crusting and
mean healing time with honey treatment were 35, 39, 28
and 43% shorter, respectively, than with acyclovir
treatment. For genital herpes, the mean duration of
attacks and pain, occurrence of crusting and mean
healing time with honey treatment were 53, 50, 49 and
59% shorter, respectively, than with acyclovir. Two cases
of labial herpes and one case of genital herpes remitted
completely with the use of honey. No side effects were
observed with repeated applications of honey, whereas
three patients developed local itching with acyclovir. The
authors came to the conclusion that topical honey
application is safe and effective in the management of
the signs and symptoms of recurrent lesions from labial
and genital herpes (9). According to this experience, we
treat children and adults with recurrent herpetic lesions
on the lips with medical honey, as soon as a new lesion is
developing. In addition, we use topical medical honey in
addition to systemic acyclovir in immunocompromized
patients with zoster to prevent secondary bacterial skin
infection and to accelerate healing of the herpetic lesions.
Medical Honey in Chronic Ocular
Surface Diseases
Albietz et al. (50) recently published the results of a study
that assessed the effect of MedihoneyTM antibacterial
honey on the ocular flora in patients with dry eye caused
by tear deficiency and/or Meibomian gland disease. In
this prospective, open-label pilot study, bacteria isolated
from the eyelid margin and conjunctiva were identified
and quantified before and at 1 and 3 months after
initiation of treatment with topical application of
antibacterial honey thrice daily. The total colony-forming
units (CFUs) isolated from each of the dry eye subgroups
before antibacterial honey use was significantly greater
than the total CFU isolated from the non-dry eye group.
Use of MedihoneyTM Antibacterial honey significantly
reduced total CFUs for the eyelids and the conjunctiva of
dry eye subjects from baseline at month 1 and 3. At month
3, the total CFUs for all dry eye subgroups were
not significantly different from those of the non-dry eye
group. A review of the medical uses of honey (8) has cited
several other reports of honey, an ancient treatment for
sore eyes, being found to be successful in modern
ophthalmology.
Comparing Different Types of Honey
A comparison of different types of honey, which is
beyond the scope of this article, may be an important
issue in future trials (24). In particular the results
obtained by Prof. Descotte from France, presented
during several international Apitherapy meetings, point
into this direction; unfortunately they have not been
published in a medline listed journal. Irish et al. (51)
found Jarrah honey (derived from Eucalyptus marginata),
which contains higher amounts of glucose oxidase, to be
significantly more effective against Candida spp. in vitro;
the activity of the other honeys including MedihoneyTM
against Candida spp. with minimal inhibitory concentra-
tions above 40% (w/v) were not distinguishable from the
activity of an artificial honey.
Minimal Requirements for Clinical Use
From a professional medical perspective honey used in
wound care should have a proven antibacterial activity
against the most important pathogens in wound infection
(S. aureus, Pseudomonas aeruginosa) (16,52) measured
with an appropriate microbiological in vitro method
(5,25,27,51,52). In addition, it should be irradiated (23)
in particular if it is used in deep or partially necrotic
wounds (53) which possess a potential of anaerobic
wound conditions. Surely, we do not criticize the
emergency care use of raw honey directly derived from
local bee keepers in countries with extremely limited
medical resources (54) in which physicians or other health
care workers do not have access to conventional wound
care products (13,55–57).
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Who Should Supervise the Use of Medical
Honey in Clinical Practice?
For safety reasons, wound care with medical honey should
always be supervised by a physician or an experienced
wound care nurse in patients with chronic complicated
wounds or with significant comorbidities. The ‘honey
approach’ to wound care must be part of a comprehensive
wound care concept. Any comorbidity which contributes to
the problems in wound healing should be diagnosed and
treated thoroughly with state of the art interventions
(e.g. bypass surgery in patients with reduced arterial
perfusion, compressive bandages in patients with chronic
venous ulcers, sufficient control of blood glucose levels in
patients with diabetic food syndrome) (58).
Honey Must be Kept in Contact
to the Wound
Medical honey dressings should keep the honey in contact
with the wound for at least 12 h, but preferably for 24 h.
Some patients apply the wound dressing overnight, so as
not to restrict their mobility during the day. If the dressing
is inappropriate, the honey may be washed out of the
wound by exudate. The clinical benefits of medical honey
including antibacterial protection, wound cleaning and pH
modulation may as a result be reduced. From our
experience (2) and the experience of others (59), the best
way to keep the honey in the wound is to soak medical
honey into a calcium-alginate or hydrofiber dressing,
which forms a gel with the honey as it absorbs the exudate.
The various registered medical honey products available,
some in the form of prepared honey-impregnated dres-
sings, have been described (14,45).
When to Use Systemic Antibiotics
Concomitantly
In case of an infected wound or in case of colonization
with a multiresistant bacterial isolate, a hospital grade,
licensed antiseptic (e.g. octenidine) is applied to the
wound in addition to MedihoneyTM on the first 2 days of
treatment. In patients with neutropenia (neutrophil count
<0.5 109 l1 or leukocyte counts <1 109 l1 and no
differential count available) systemic antibiotics have to
be administered concomitantly after a local wound swab
has been taken if fever or local sign reveals soft tissue
infection. With hospitals facing increasing problems of
bacterial resistance, it is important to note that the use of
medical honey has never been observed to foster bacterial
resistance (20).
Frequency of Dressing Changes
The frequency of dressing changes depends on the
amount of exudate. In early stages, fresh surgical
wounds infected with pathogenic bacteria may necessitate
a dressing change twice a day. In stable wound care
situations, the MedihoneyTM dressing has been left in
place for up to 7 days (58,60). Prospective studies
confirming the safety of such an extended dressing
change interval are not yet available.
Compliance Issues
Dunford et al. (61) undertook a four-center feasibility study
to determine whether MedihoneyTM is an acceptable
treatment for patients with leg ulcers in terms of pain
relief, odour control and overall patient satisfaction. A total
of 40 patients whose leg ulcers had not responded to 12
weeks of compression therapy were recruited. Medihoney
dressings were applied on their ulcers for the 12-week study
period. All other aspects of their care, including the use of
compression bandaging, remained unchanged. Overall,
ulcer pain and size decreased significantly and odorous
wounds were deodorized promptly.
These results revealed a high patient acceptance for and
concordance with this treatment. The same first author
reported the care of an adolescent with multiple wounds,
infected with resistant bacterial pathogens after menin-
gococcal sepsis and limb amputation (62). Before the use
of medical honey, each dressing change had to be
performed under general anaesthesia to alleviate pain
and anxiety. Shortly after the introduction of medical
honey dressings, the wounds improved and dressing
changes could be performed without any analgesic
medication. We have had similar experiences with
children in our clinic. If the medical honey dressing is
completely moistened with sterile Ringer solution, it can
easily and painlessly be removed without any negative
attachment to the wound. In our unit and our wound
care ambulance, parents or relatives are educated in the
aseptic procedure of the dressing change and thus, they
are enabled to perform it at home.
Adverse Effects
There are two important adverse effects related to the use
of medical honey. We have observed in about 5% of our
patients stinging pain after administration. This problem
may be circumvented by the conditioning of the wound
surface with a sterile anaesthetic cream. Unfortunately,
local anaesthetics cause vasoconstriction. Thus, the
application of an anaesthetic to the wound surface may
result in an objectionable reduction of local perfusion. In
some patients who experienced pain after administration,
treatment with medical honey had to be stopped (16) or
postponed to later phases of wound healing after the
acute inflammatory process has been controlled by other
approaches. Two of 150 patients from our patient
population showed reproducible local atopic reactions
to MedihoneyTM. Both children had an underlying
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atopic disposition. We are not aware of any severe sys-
temic atopic reaction related to the use of medical honey
from our experience and from the published literature.
Cost Issues
Ingle et al. (63) from South Africa performed a randomized
controlled trail to investigated the use of natural honey
(monofloral aloe honey) in shallow wounds, donor sites for
skin grafting and partial thickness burns in 44 goldmine
workers. They compared this group with another group of
43 workers whose wounds were treated with IntraSiteTM
Gel (Smith and Nephew Ltd). They did not find significant
differences in healing time, adverse events (itching, pain)
and satisfaction with treatment but the average cost of the
use of honey was 4% that of IntraSiteTM treatment. More
prospective studies investigating the overall cost of treat-
ment with medical honey compared with conventional
wound care approaches are awaited (64) in particular in
chronic, recalcitrant wounds. In clinical practice, the use of
calcium alginate or hydrofiber gauzes and semipermeable
dressings to keep the honey in the wound has to be added to
the acquisition cost of the medical honey. To contain the
demands on personnel resources, it would be of out-
standing interest to develop ready to use medical honey
dressings, which have to be changed only every 2–3 days
even in acute wound care situations.
WoundViewer Database
We recently developed a database for the standardized
prospective collection of datasets considering the clinical
use of medical honey products in wound care to foster the
collection of clinical evidence to help design prospective
comparative studies in the near future.
Conclusion
More prospective randomized studies on a wider range of
types of wounds are needed to confirm the safety and
efficacy of medical honey in wound care (65).
Nonetheless, the current evidence (15) confirming the
antibacterial properties and additional beneficial effects
of medical honey on wound healing should encourage
other wound care professionals to use CE-certified honey
dressings with standardized antibacterial activity, such as
MedihoneyTM products, as an alternative treatment
approach in wounds of different natures.
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